Torigen, Inc. is a biotechnology startup with a focus on veterinary cancer care. The company's mission is to improve the lives of pets by leveraging their immune systems to revolutionize cancer treatment with personalized vaccines. With cancer affecting nearly 10 million companion animals annually, Torigen aims to provide pet owners with more treatment options. Their autologous prescription product, supported by over a decade of research, utilizes the patient's own tumor cells to create a tailored cancer treatment. Torigen's goal is to collaborate with veterinarians early in the diagnostic process and empower them to be part of the solution.
Founded in 2013, Torigen operates in the Biotechnology and Health Care industries. In November 2022, the company secured a $13.00M Series A investment from a consortium of investors including Gaingels, SoGal Ventures, Advantage Capital Partners, Connecticut Innovations, Sidecar Angels, Emerald Development Managers, Ironwood Capital Connecticut, Kema Fund, UConn Innovation Fund, and Werth Ventures.
